ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 0586 • ACR Convergence 2022

    Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse

    Shuzo Sato1, Xian Zhang2, Naoki Matsuoka1, Yuya Sumichika1, Kenji Saito1, Shuhei Yoshida1, Haruki Matsumoto1, Jumpei Temmoku1, Yuya Fujita1, Tomoyuki Asano1, Hiroshi Watanabe1 and Kiyoshi Migita1, 1Fukushima Medical University, Fukushima, Japan, 2Medical University of South Carolina, Charleston, SC

    Background/Purpose: Friend leukemia virus integration 1 (Fli-1) belongs to the Ets family of transcription factors and plays an important role in the development of lupus…
  • Abstract Number: 1129 • ACR Convergence 2022

    Integrated High-throughput Proteomics and Machine Learning Analysis in Systemic Lupus Erythematosus Patients Identify Distinctive Clinical Profiles and Novel Biomarkers Related to Cardiovascular Risk and Lupus Nephropathy

    Chary Lopez-Pedrera1, Tomás Cerdó2, María Ángeles Aguirre-Zamorano3, Laura Muñoz-Barrera1, Ismael Sánchez-Pareja2, Pilar Font1, María Carmen Ábalos-Aguilera4, Pedro Ortiz-Buitrago4, Nuria Barbarroja1, Eduardo Collantes1, Rafaela Ortega-Castro1 and Carlos Pérez-Sánchez1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 3Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 4Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain

    Background/Purpose: Systemic lupus erythematosus (SLE) is a remarkably heterogeneous autoimmune disease. At present, our knowledge of serum protein patterns related to cardiovascular (CV) risk and…
  • Abstract Number: 1483 • ACR Convergence 2022

    Etiology of Elevated Serum Creatinine in Patients with Systemic Lupus Erythematosus at Presentation and Association of Crescents in Renal Biopsy with Rapidly Progressive Renal Failure in a Lupus Cohort

    Rajat Kharbanda, Able Lawrence and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: Systemic lupus erythematosus (SLE) commonly involve kidney, with increase in creatinine due to lupus related or unrelated cause. Renal biopsy remains gold standard in…
  • Abstract Number: 2078 • ACR Convergence 2022

    Mesangial Lupus Nephritis: Long Term Outcomes

    KONSTANTINOS TSELIOS1, Dafna Gladman2, Jiandong Su3 and Murray Urowitz4, 1McMaster University, Population Health Research Institute, Hamilton, ON, Canada, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada

    Background/Purpose: Mesangial lupus nephritis (LN class II) is generally considered benign with minimal potential for developing advanced chronic kidney disease (CKD). However, a certain proportion…
  • Abstract Number: 0334 • ACR Convergence 2022

    Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records

    Zara Izadi1, Alfredo Aguirre2, Christine Anastasiou2, Julia Kay3, Gabriela Schmajuk4 and Jinoos Yazdany5, 1University of California San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3UCSF, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA, 5UCSF, San Rafael, CA

    Background/Purpose: Real-world data could provide valuable information in the study of lupus nephritis (LN), if these cases could be reliably identified. A lack of ability…
  • Abstract Number: 0630 • ACR Convergence 2022

    Ferroptosis of CD163+ Tissue Infiltrating Macrophages in Lupus Nephritis

    Qi Cheng, Huaxiang Wu and Yan Du, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China

    Background/Purpose: Lupus nephritis (LN) is one of the most common complications of systemic lupus erythematosus (SLE), with high morbidity and mortality. Despite a better understanding…
  • Abstract Number: 1135 • ACR Convergence 2022

    Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy

    Shudan Wang1, Anna Broder2, Daming Shao3, Vartika Kesarwani4, Brianna Lally5, Masako Suzuki6, J. Michelle Kahlenberg7, Jennifer Aguilan6 and Simone Sidoli6, 1Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, 2Hackensack University Medical Center, Hackensack, NJ, 3Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, 4University of Connecticut, Farmington, CT, 5University of Wisconsin Hospitals and Clinics, Madison, WI, 6Albert Einstein College of Medicine, Bronx, NY, 7University of Michigan, Ann Arbor, MI

    Background/Purpose: The complement system has an important and underrecognized role in mediating tubulointerstitial disease in lupus nephritis (LN). The omics big data allows for identifying…
  • Abstract Number: 1636 • ACR Convergence 2022

    Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort

    Murray Urowitz1, Mary E. Georgiou2, Jiandong Su3, Anne MacKinnon3, Yulia Green4, Kerry Gairy2, Roger A Levy5 and Patricia C. Juliao6, 1University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 2GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, 3University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Division of Rheumatology, Toronto, ON, Canada, 4GlaxoSmithKline, Clinical Development, Brentford, United Kingdom, 5GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 6GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA

    Background/Purpose: Approximately 40% of adult patients with SLE develop LN, which can lead to end-stage kidney disease (ESKD).1 Renal response is used in clinical trials…
  • Abstract Number: 2082 • ACR Convergence 2022

    A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy

    Dario Roccatello1, Savino Sciascia2, Carla Naretto1, Mirella Alpa1, Roberta Fenoglio1, Michela Ferro1, Giacomo Quattrocchio1, Elena Rubini1, Elnaz Rahbani1, Vittorio Modena1 and Daniela Rossi1, 1University of Turin, Turin, Italy, 2University of Turin, Torino, Italy

    Background/Purpose: We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of…
  • Abstract Number: 0336 • ACR Convergence 2022

    Machine Learning Approach for the Prediction of Lupus Nephritis Renal Flares Using Polygenic Risk Score and Electronic Health Record

    Yi-Ming Chen1, Tzu-Hung Hsiao1, Seng-Cho Chou2 and Chi-Wei Chung2, 1Taichung Veterans General Hospital, Taichung, Taiwan, 2Department of Information Management, National Taiwan University, Taipei, Taiwan

    Background/Purpose: Lupus nephritis (LN) flares are associated with risks of renal failure and mortality in patients with systemic lupus erythematous (SLE). It is critical to…
  • Abstract Number: 0634 • ACR Convergence 2022

    Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis

    Minh Dien Duong1, Shudan Wang2, Daniel Schwartz3, Wenzhu B. Mowrey4, Anna Broder5 and Beatrice Goilav6, 1The Children's Hospital of Montefiore / Albert Einstein College of Medicine, Bronx, NY, 2Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, 3Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, 4Albert Einstein College of Medicine, Bronx, NY, 5Hackensack University Medical Center, Hackensack, NJ, 6Children's Hospital of Montefiore / Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Kidney biopsy is a gold standard for diagnosis and prognostication of lupus nephritis (LN). While interstitial fibrosis and tubular atrophy (IFTA) predict progression to…
  • Abstract Number: 1273 • ACR Convergence 2022

    Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: Data Availability and Preliminary Measure Performance in the RISE Registry

    April Jorge1, Alfredo Aguirre2, April Barnado3, Bonnie Bermas4, Candace Feldman5, Shraddha Jatwani6, Alex Limanni7, JoAnn Zell8, Claire Barber9, Ali Duarte-Garcia10, Shivani Garg11, Jing Li2, Gabriela Schmajuk12, Jinoos Yazdany13 and Christie Bartels14, 1Massachusetts General Hospital, Boston, MA, 2University of California, San Francisco, San Francisco, CA, 3Vanderbilt University Medical Center, Nashville, TN, 4UT Southwestern, Dallas, TX, 5Brigham and Women's Hospital, Boston, MA, 6Albert Einstein Medical Center, Ambler, PA, 7Self, Dallas, TX, 8University of Colorado Anschutz Medical Campus, Denver, CO, 9University of Calgary, Calgary, AB, Canada, 10Mayo Clinic, Rochester, MN, 11University of Madison, School of Medicine and Public Health, Madison, WI, 12UCSF / SFVA, San Francisco, CA, 13UCSF, San Francisco, CA, 14University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Digital quality measures can facilitate monitoring and improvement of health care quality on a population level. As part of a CDC-funded ACR initiative to…
  • Abstract Number: 1653 • ACR Convergence 2022

    Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies

    Cristina Arriens1, Samir Parikh2, Lucy Hodge3, Chris Mela4 and Henry Leher5, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2The Ohio State University, Columbus, OH, 3Aurinia Pharmaceuticals, Seattle, WA, 4Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada, 5Aurinia Pharmaceuticals Inc, Rockville, MD

    Background/Purpose: In the Phase 3 AURORA 1 study, the addition of voclosporin to mycophenolate mofetil (MMF) and low-dose steroids led to significant reductions in proteinuria…
  • Abstract Number: 2093 • ACR Convergence 2022

    Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort

    Farah Tamirou and Frédéric A. Houssiau, Cliniques Universitaires Saint-Luc, Brussels, Belgium

    Background/Purpose: While long-term follow-up (FU) is needed to unmask poor outcome in lupus nephritis (LN), most clinical trials evaluate outcome measures at short-term. Early endpoints…
  • Abstract Number: 0341 • ACR Convergence 2022

    Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice

    YoungEun Kim1, Eun-Ju Lee1, Soo Min Ahn1, Ji Seon Oh2, Seokchan Hong1, Chang Keun Lee1, Bin Yoo1 and Yong Gil Kim1, 1Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 2Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea

    Background/Purpose: Despite improvements in the treatment of lupus nephritis (LN), the prognosis remains unsatisfactory, and a need for non-invasive biomarkers for early detection endures. Previously,…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology